Canada markets closed

Creative Medical Technology Holdings, Inc. (CELZ)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4787-0.0033 (-0.68%)
At close: 04:00PM EDT
0.4664 -0.01 (-2.57%)
After hours: 06:47PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • B
    Bobbie Browns Anger Manager
    Man.. talk about what once was..
  • J
    3.5 months of sp stagnation, ... will this at least hit .10 by Dec. ?
  • B
    Bobbie Browns Anger Manager
    have they received a warning of being delisted off the big board?
  • A
    Positive press release on the Company's StemSpine 2 year study. It can only go up from it's current low.
  • L
    When is the next RS
  • B
    Bobbie Browns Anger Manager
    This gap up will provide a quick clean up of profit stops and then fly high after an hour or two into the day, with this news. That's my hope anyway.
  • R
    You ask me what I am writing about. I am writing about a paradigm change in medicine. For the record I am a long, of 2.5 years in CELZ, and TSOI. I only have 8,000 shares left of CELZ. I am not happy the way it is going. The problem is not the people who are working to usher in a new day in medicine. The problem is the organized massacre of these companies. The MM’s, and shorts are the bit players for the big money that wants these companies dead. When you have unlimited access, and money It is very easy to destroy something, or force it into an untenable position such as an RS, using a spiral of death financing scheme, and then blame the people that have poured their sole into its creation. They are the ones that can least defend themselves. The MM’s and shorts are only interested in the shares they can collect the money on, then bury by causing the death of the company. The big money behind them is interested in killing the potential competition and steeling the new technology when the companies that developed it are driven into bankruptcy.
    This is where you start your tirade, that I don’t know what I am talking about. I was doing technology development in the Silicon Valley when you were in grade school, I know every way this works. The reality is this technology will ultimately win out over the people like you that have nothing to offer.
  • m
    Looks like Sloan Kettering has beat you to the finish line
  • R
    Where is the heck are the press releases for this?????
  • m
    This stock is a shameful SCAM. I predicted it will be less than $1 in less than 6 month after another shameful RS. They surprised all with an atonished .48…. And now they write ( same all pattern) a “peer review” about one of their “ so many products and achievements”… Soon another RS before returning to OTC world… SCAM!!!!
  • s
    This stock and the horrible leadership team ruined my life.
  • T
    PHOENIX, Feb. 10, 2021 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings announced today new data explaining mechanisms of action of its patented OvaStem® female infertility/ovarian failure treatment.  OvaStem®, which is covered by issued patent #10,792,310, involves injection of stem cells into dysfunctional ovaries and has been demonstrated to induce fertility, as well as restore hormone levels.
    The data, which are covered in a newly filed patent application, demonstrate that mesenchymal stem cell injection results in generation of T regulatory cells.  These cells are a type of immune cell which the Company has previously patented for regeneration of lumbar discs (US Patent #10,842,815).  Importantly, depletion of T regulatory cells resulted in negation of the beneficial effects of stem cells, whereas exogenous administration of T regulatory cells are capable of restoring ovarian function.
    "Cellular therapy is making significant advances in the treatment of cancer, degenerative diseases, and autoimmunity." Said Dr. Amit Patel, Board Member of the Company and co-inventor of the patent. "We are pleased to discover this interesting interaction between mesenchymal stem cells and T regulatory cells in prevention of ovarian failure and restoration of function.  By elucidating mechanisms, we feel we are making progress towards eventual filing with the FDA for initiation of clinical trials."
    Although the menopause market is believed to be approximately $600 billion[1], the Company is focusing on the initial indication of premature ovarian failure.  Premature ovarian failure occurs in woman under 40 who experience degeneration of ovaries from a variety of conditions.  The Company has demonstrated efficacy of autologous (patient's own stem cells) and allogeneic (universal donor) in animal models of this condition. 
    "Despite having a wide variety of cellular products in development, there appears to be a common theme of interaction between mesenchymal stem cells and T regulatory cells." Said Timothy Warbington, President and CEO of the Company.  "Today's discovery that T regulatory cells are effective in treatment of ovarian failure lends more scientific support to OvaStem®, which we hope will accelerate our path towards FDA clinical trials to treat this condition."
    About Creative Medical Technology Holdings 
    Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine/stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC under the ticker symbol CELZ. For further information about the company, please visit   
    Forward Looking Statements 
    OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website
  • O
    Creative Medical Technology issued a press release before the market open on Friday and here are some key highlights:
    ·         Receipt of detailed correspondence from the FDA regarding necessary modifications to IND #27375 for using ImmCelz® regenerative immunotherapy for the treatment of stroke.
    ·         The Company’s ImmCelz® product utilizes a patient’s own blood cells that have been “reprogrammed” in the laboratory by culturing with established universal donor stem cells, followed by re-infusion into the patient.
    ·         Efficacy in animal models has been demonstrated in heart failure, kidney failure, multiple sclerosis, liver failure and type 1 diabetes.
    ·         Given that this is the first time such a product was brought to the FDA, the Company appreciates the detailed analysis provided by the Agency, and the constructive feedback.
    “I am grateful for our scientific and clinical team which has assembled the ImmCelz® IND proposal for the FDA, which resulted in detailed comments and advice for moving forward. Our team is already working on it.” said Timothy Warbington, President and CEO.
  • V
    Stem Cell Injections Show Early Promise Against Spinal Cord Injuries
    BY DENISE MANN HealthDay Reporter


    MONDAY, March 1, 2021 (HealthDay News) -- Spinal cord injuries can be devastating to the more than 17,000 Americans who suffer them each year. But many patients may have new reason for hope: Early research suggests infusions of stem cells could help them regain lost sensation and movement.

    These improvements may occur within days or weeks of receiving the stem cell therapy, and can last at least six months, according to the small study.

    "This is exciting because there are really limited treatment options for patients with spinal cord injury," said Dr. Griffin Baum, a spine surgeon at Lenox Hill Hospital in New York City, who was not involved in the research.

    The 13 people in the study had injured, but not severed, their spinal cords. Many experienced loss of motor function and coordination and/or bowel and bladder dysfunction as a result of their injury.

    Working with scientists in Japan, researchers at Yale University took mesenchymal stem cells from participants' own bone marrow, multiplied them in the lab and intravenously infused them back around 40 days after their injury. Mesenchymal stem cells are adult stem cells found in bone marrow, skin and fat tissue that can morph into many different cell types. This therapy, called Stemirac, was fast-tracked for approval in Japan in 2018 amid controversy due to lack of data supporting its use.

    Twelve of the 13 people in the new study showed improvement in important sensory or motor functions by six months after the infusion, and more than half made substantial gains in walking ability or use of their hands. These improvements were illustrated by changes on the American Spinal Injury Association impairment scale, which measures injury severity, the researchers said.

    According to study co-author Dr. Stephen Waxman, "The idea that we may be able to restore function after injury to the brain and spinal cord using the patient's own stem cells has intrigued us for years." Waxman is a professor of neurology, neuroscience and pharmacology at Yale School of Medicine in New Haven, Conn.

    "Now we have a hint, in humans, that it may be possible," Waxman said in a Yale news release.

    Exactly how, or even if, these stem cells help reverse damage is not fully understood yet, but the researchers suspect they may cool inflammation and/or develop into neurons that can replace those damaged in the injury. Because they are infused, the stem cells may affect other parts of the central nervous system outside of the spinal cord, which could also explain some of the benefits.

    Importantly, the experimental treatment was safe with no serious side effects seen in any of the participants. Still there was no placebo or "dummy" group for comparison, so it's possible that any improvements could have been the result of spontaneous recovery, which occurs in people with spinal cord injuries, the researchers noted.

    Baum, while intrigued by the findings, was quick to caution that it's too early to make any sweeping claims about the stem cell treatment.

    "I think the results should be taken with a grain of salt, and enthusiasm should be tempered. More research is required to see whether, on a larger scale, these results could be replicated and statistically significant," said Baum, who is also an assistant professor of neurosurgery at the Zucker School of Medicine at Hofstra/Northwell in Hempstead, N.Y.

    Still, there is reason for hope, according to Mike Modo, a professor of radiology and bioengineering at the University of Pittsburgh Institute for Regenerative Medicine. "The amazing thing here is that after just a single infusion of stem cells, we are seeing benefits out six months," said Modo, who was not involved in the study.

    A big plus is the fact that the therapy is given via intravenous infusion, which is much less invasive and risky than other stem cell delivery methods, he added. "IV delivery is minimal in terms of impact on patients, and that is the big contribution of this paper," Modo said.

    But the research is still in its infancy and much more needs to be understood before it reaches the bedside, he noted.

    The study results were published Feb. 18 in Clinical Neurology and Neurosurgery.

    More information

    Learn more about the promise of stem cell therapy at the U.S. National Institutes of Health.

    SOURCES: Griffin Baum, MD, spine surgeon, Lenox Hill Hospital, and assistant professor, neurosurgery, Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; Mike Modo, PhD, professor, radiology and bioengineering, University of Pittsburgh McGowan Institute for Regenerative Medicine, Pittsburgh, Penn.; Yale University, news release, Feb. 22, 2021; Clinical Neurology and Neurosurgery, Feb. 18, 2021, online
    US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.
    US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.
  • s
    The inventor of ImmCelz is legit......

    Dr. Amit Patel Named Chief of Cardiac Surgery
    Amit Patel, M.D., M.S., professor of surgery and director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah School of Medicine, has been named Chief of Cardiac Surgery at the University of Miami Health System. Patel is a leader in the development of new therapies for cardiac diseases that incorporate the latest advances in open surgical reconstruction, trans-catheter interventions, stem cells, genetic approaches, and matrix therapies.

    Patel has served as national principal investigator in several first-in-human trials and has numerous patents, publications, and national and international presentations. He is a leader in clinical translation and innovation with a track record of entrepreneurship intended to bring forth novel devices and biologics that may ultimately represent new treatments and cures.

    He received his M.D. from Case Western Reserve University, did his internship and residency in surgery at Baylor University Medical Center, and completed a fellowship in cardiothoracic surgery at the University of Pittsburgh.
  • S
    If you are here to make a quick buck, awesome (in earnest) for you. If you are here to get in ground floor on something that could be a game-changer (to the medical science field/healthcare/your longterm financial future), then do your own DD into their existing offerings (already in the market: a male & female sexual dysfunction; an in-office treatment using a person's own stem cells that, likely has ramped down massively considering COVID). Then, in pilot, they have StemSpine for degenerative disc disease... In preclinical: Amniostem for STROKE. & also in preclinical (TWO IN ONE WEEK): reversing liver disease and affecting heart attack outcomes (covers data in which mice with restricted blood flow to the heart had significantly improved survival when treated with ImmCelz® as compared to control mice). Please Google and study it on your own.

    "The role of the immune system in numerous aspects of regenerative medicine can not be overstated." Said Dr. Amit Patel, Board Member of the Company and co-inventor of the patent. "The data described today, while preliminary, supports the belief that ImmCelz®, which is a "regenerative immunotherapy" can be applied across a broad range of conditions."
  • C
    BIG days ahead for Creative Medical Technology Holdings (CELZ) presenting at the World Stem Cell Summit. ImmCelz technology will be presented by Dr. Thomas Ichim at the Investor's Forum on Thursday at noon EST, potentially yielding financial and clinical trial partners.

    As a bonus, the Summit has different breakout sessions that happen at the same time throughout the day, and attendees just go to the ones they are there to see. ImmCelz is being presented during lunch, per the agenda, when no other breakout sessions are going on. This allows anyone in attendance to go to the presentation without missing anything else they are there for, creating even more potential for new individual investors to buy in. MAXIMUM EXPOSURE!

    Dr. Camillo Ricordi, pioneer of cellular therapies for diabetes and new Scientific Advisory Board Member of the Company, will be discussing his work on Covid Thursday as well. His presence means even more exposure for the company.

    Plus the anticipation of FDA approval for ImmCelz stroke human trials to begin possibly coming in the near future. I can't see the company being there to present this new technology without having confidence of an approval soon.

    CELZ is going to be in the spotlight on one of the biggest world stages. It should be an exciting rest of the week!
  • C
    to everyone coming over here for the first time:

    they submitted an IND for a stroke study for Immcelz on March 4th and received their IND number around the 13th. they are planning ba Phase 1 study.

    they are also pursuing a product to help reverse damage to ovaries to increase fertility. no Phase 1 studies.

    they have added several indications to Immcelz patent based on animal studies.

    they don't inject the stem cells into the person for Immcelz. they expose the patients immune cells to it in order to "reset" them. the cell line used has been injected into patients at U of Miami for Covid and had a good response.

    they also have stem cell kits they currently sell for ED and female sexual dysfunction. they have made about $167k per year for the last 2 years on that. they expected more last year but lost time due to Covid
    they have pursued new sites in the meantime and a clinic in Texas and Arizona have had very good response. the response for the ED is seen relatively soon and continues to increase for up to a year at least.

    they have had very good reduction in back pain in a trial for SpineStem in the US and had good response in Europe as well. they are looking for sites to enroll the first 100 patients into a registry study for this.

    they are also working on a website to match patients with procedures and possibly products. they expect to have something out later this year

    they have been working to reduce debt and have recently had a reduction in outstanding share count.

    there's also websites for Caverstem and Femcelz if you want to see more about how the kits are used
  • C
    "Cellular immunotherapy has commanded extremely lucrative valuations for companies in early stages of clinical trials." Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "We believe for regenerative immunotherapy products such as ImmCelz® to attract similar valuations, understanding of biological mechanisms of action is important. I commend our scientific collaborators for their work that resulted in this current patent filing."